Literature DB >> 16780888

The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.

V Dhawan1, S Dhoat, A J Williams, A Dimarco, S Pal, A Forbes, A Tobías, P Martinez-Martin, K Ray Chaudhuri.   

Abstract

In this study we have explored the nature and range of sleep dysfunction that occurs in untreated Parkinson's disease (PD) comparing data obtained from the use of the Parkinson's disease sleep scale (PDSS) in an untreated PD patient group compared to advanced PD and healthy controls. 25 untreated (drug-naive, DNPD) PD patients (mean age 66.9 years, range 53-80, 18 males) completed the validated Parkinson's disease sleep scale (PDSS), mean duration of PD was 2.1 years (1-10, up to 4 years in all except one patient with tremulous PD reporting tremor duration of 10 years) and mean Hoehn and Yahr score 1.9 (1-3). Data were compared to 34 advanced PD (mean age 70.2 years, range 51-88, 23 male), mean duration of PD 11 years (range 4-22), mean Hoehn and Yahr score 3.4 (3-5) and PDSS data obtained from 131 healthy controls (mean age 66.6 years, range 50-93, 56 males). Total PDSS scores and PDSS sub-items, except PDSS item 2, were highly significantly different (p<0.001) between DNPD, advanced PD and controls. Controls reported higher mean PDSS scores than both groups of patients, and advanced cases reported lower (mean+/-S.D.) PDSS scores (86.95+/-20.78) than drug-naive (105.72+/-21.5) (p<0.001). Logistic regression analysis showed that items PDSS8 (nocturia), PDSS11 (cramps), PDSS12 (dystonia), PDSS13 (tremor), and PDSS15 (daytime somnolence) were significantly impaired in DNPD compared to controls while PDSS7 (nighttime hallucinations) additionally separated advanced PD from DNPD. In a subgroup of 11 advanced PD cases (mean age 62 years, range=49-84 years, mean Hoehn and Yahr score 2.5, range=1-3) with high Epworth Sleepiness Scale (ESS) scores (mean 14.5), low item 15 PDSS score (mean 4.7) and complaints of severe daytime sleepiness, underwent detailed overnight polysomnography (PSG) studies, all showing abnormal sleep patterns. We conclude that nocturia, nighttime cramps, dystonia, tremor and daytime somnolence seem to be the important nocturnal disabilities in DNPD and some of these symptoms may be reminiscent of "off" period related symptoms even though patients are untreated. Furthermore, polysomnography in "sleepy" PD patients may help diagnose unrecognised conditions such as periodic limb movement of sleep (PLMS), obstructive sleep apnoea (OSA) and REM Sleep Behaviour Disorder.

Entities:  

Mesh:

Year:  2006        PMID: 16780888     DOI: 10.1016/j.jns.2006.05.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  33 in total

1.  Sleep disturbances in untreated Parkinson's disease.

Authors:  Jitka Bušková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Karel Sonka; Robert Jech; Jan Roth; Evžen Růžička
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

2.  Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients.

Authors:  Roberto Erro; Gabriella Santangelo; Marina Picillo; Carmine Vitale; Marianna Amboni; Katia Longo; Angela Costagliola; Maria Teresa Pellecchia; Roberto Allocca; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Paolo Barone
Journal:  J Neurol       Date:  2012-02-07       Impact factor: 4.849

3.  Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls.

Authors:  Charlene Gamaldo; Amy R Benbrook; Richard P Allen; Oluwamurewa Oguntimein; Christopher J Earley
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

4.  Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.

Authors:  Shahmir Sohail; Lei Yu; Julie A Schneider; David A Bennett; Aron S Buchman; Andrew S P Lim
Journal:  Mov Disord       Date:  2017-10-30       Impact factor: 10.338

5.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

6.  Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

Authors:  Aleksandar Videnovic; Charleston Noble; Kathryn J Reid; Jie Peng; Fred W Turek; Angelica Marconi; Alfred W Rademaker; Tanya Simuni; Cindy Zadikoff; Phyllis C Zee
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 7.  Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease.

Authors:  Fatai Salawu; Abdulfatai Olokoba
Journal:  Oman Med J       Date:  2015-01

Review 8.  Parkinson's disease and sleep/wake disturbances.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Koichi Hirata
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 9.  Treatment of Sleep Dysfunction in Parkinson's Disease.

Authors:  Amy W Amara; Lana M Chahine; Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2017-07       Impact factor: 3.598

Review 10.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.